A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-12-23
Target enrollment:
Participant gender:
Summary
This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of
multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or MF due to
polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid
leukemia (AML).